Related Experiment Video
Updated: Oct 24, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.2K
Nivolumab Induced Psoriasis Successfully Treated With Acitretin
Journal of Drugs in Dermatology : JDD
|August 16, 2021
Summary
Immunotherapy, a novel cancer treatment, harnesses the immune system to combat solid tumors. Immune checkpoint blockade is a key strategy to enhance the body's anti-tumor response.
Area of Science:
- Oncology
- Immunology
Background:
- Immunotherapy is an emerging treatment modality for various solid tumors.
- It functions by utilizing the patient's immune system to initiate an anti-tumor response.
Purpose of the Study:
- To explore the role of immunotherapy in cancer treatment.
- To highlight immune checkpoint blockade as a mechanism for enhancing anti-tumor immunity.
Main Methods:
- Review of current research on immunotherapy.
- Analysis of the mechanisms underlying immune checkpoint blockade.
Main Results:
- Immunotherapy shows promise as an alternative cancer treatment.
- Immune checkpoint blockade effectively stimulates anti-tumor immune responses.
Conclusions:
- Immunotherapy represents a significant advancement in cancer treatment strategies.
- Targeting immune checkpoints is a viable approach to augment anti-cancer immunity.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
290
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
290
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
262
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
262
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
246
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
246
01:30Skin Cancer
4.9K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.9K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
277
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
277
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
306
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
306